MOTS-c Monitoring Schedule: Labs & Exams Every Patient Needs
See the public record for MOTS-c
At a glance
- FDA status / Not an approved drug, and not a component of one [1]
- Studies of injected MOTS-c in people / None found in FDA's July 2026 review [1]
- Human dose / None established; no human dosing study [1]
- Blood-level data for an injected dose / None in humans or live animals [1]
- Adverse-event reports / None retrieved in FDA's search through March 9, 2025 [1]
- Main stated injection concern / Immune reaction from peptide aggregation and impurities [1][4]
- Sport / Prohibited at all times by WADA, section S4.4.1 [5]
Does MOTS-c have a monitoring schedule?
No. A monitoring schedule comes from human dosing studies: what was given, what blood levels followed, which labs changed. FDA's July 2026 review found no clinical study in which MOTS-c was given to humans, and the 12 papers the nominator cited were not clinical studies [1].
The 5 mg and 10 mg subcutaneous amounts were the nominated products FDA reviewed for compounding, not a trial regimen. The rodent doses of 0.5 to 15 mg/kg cannot be converted into a human dose [1].
What has been measured in people
Human measurements so far are of the body's own MOTS-c, not an injected product. In a randomized study of 30 healthy adults, 10 doing endurance exercise, 10 resistance exercise and 10 controls, circulating humanin rose after endurance exercise while MOTS-c showed only a trend to increase, and plasma levels were not related to fitness [3]. A separate study found exercise raises endogenous MOTS-c in muscle and in circulation [2]. In neither did anyone receive MOTS-c.
Why no lab list can be built
All of the pharmacology comes from cells and rodents. In mice, injected MOTS-c prevented diet-induced and age-dependent insulin resistance and diet-induced obesity, with skeletal muscle the main target and AMPK activated [6]. FDA found no pharmacokinetic data for MOTS-c in humans or in live animals, the only kinetic observation being rapid breakdown in human blood in vitro, and it identified no animal toxicity studies [1]. With none of these data, there is no human basis for a first check, an interval or a threshold.
What is documented to watch for
FDA's stated concern for an injected peptide of this kind is immunogenicity, an immune reaction from aggregation and peptide-related impurities [1][4]. Its adverse-event database search through March 9, 2025 retrieved no MOTS-c reports [1]. That is an absence of reports, not evidence that repeated injection is safe.
Regulatory status
MOTS-c appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or on FDA's list for outsourcing facilities (updated March 21, 2025) [7][8][9]. FDA's page on bulk substances that may raise significant safety risks lists it only in the table of substances nominated but withdrawn; removal from category 2 was not a finding that it is safe [4]. FDA staff proposed that MOTS-c not be added to the pharmacy bulks list [1]. FDA's Pharmacy Compounding Advisory Committee voted in favour of adding it on July 23, 2026; that vote is advice only and is not binding [10][11].
HHS's draft enforcement-discretion policy, filed October 28, 2026, names MOTS-c among six peptides. For MOTS-c acetate given by subcutaneous or intramuscular injection, it says HHS does not intend to take enforcement action against certain state-licensed pharmacies, federal facilities and licensed physicians if the policy's conditions are met. The notice states it is not binding on HHS or the public [11][12]. WADA names MOTS-c in S4.4.1 (AMPK activators), prohibited at all times, in and out of competition [5][13].
Frequently asked questions
Do I need blood tests while using MOTS-c?
What dose is used in studies?
Is MOTS-c FDA-approved?
Is MOTS-c banned in sport?
References
Show all 13 referencesHide references
- U.S. Food and Drug Administration.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.